Palatin Technologies Files 8-K

TL;DR

Palatin Tech filed an 8-K on Nov 6 for Nov 5 events - material agreement, other stuff, and financials.

AI Summary

Palatin Technologies, Inc. filed an 8-K on November 6, 2025, reporting on events that occurred on November 5, 2025. The filing indicates the entry into a material definitive agreement, other events, and financial statements and exhibits. Specific details regarding the agreement or financial information were not provided in the excerpt.

Why It Matters

This 8-K filing signals significant corporate activity for Palatin Technologies, potentially involving new agreements or financial updates that could impact investors.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant business changes, but lacks specific details to fully assess the risk.

Key Players & Entities

• Palatin Technologies, Inc. (company) — Registrant
• November 5, 2025 (date) — Earliest event reported
• November 6, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 001-15543 (identifier) — Commission File Number
• 95-4078884 (identifier) — IRS Employer Identification No.
• 103 Carnegie Center Drive , Suite 300 , Princeton , NJ 08512 (address) — Address of principal executive offices
• ( 609 ) 495-2200 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share PTN 1 NYSE American Ind
• $6.50 — at a combined public offering price of $6.50 per share of common stock and accompany
• $8.125 — Warrant will have an exercise price of $8.125 per share and will be immediately exerc
• $15.8 million — enses, are expected to be approximately $15.8 million. In addition, Palatin has granted the u
• $0.0001 — rcised in full at a nominal exercise of $0.0001 per share and may not be exercised to t
• $6.0 m — stockholder's equity to be greater than $6.0 million, after reflecting all quarter end
• $8.8 — gust 2025, which resulted in revenue of $8.8 in the quarter ended September 30, 2025
• $14.7 million — f $15.8 million in gross proceeds, with $14.7 million of net proceeds expected to close Novem
• $6.0 million — holders' Equity Rule ") of greater than $6.0 million of stockholders' equity, and meeting al

Filing Documents

• ptn_8k.htm (8-K) — 37KB
• ptn_ex11.htm (EX-1.1) — 267KB
• ptn_ex41.htm (EX-4.1) — 91KB
• ptn_ex42.htm (EX-4.2) — 97KB
• ptn_ex43.htm (EX-4.3) — 97KB
• ptn_ex991.htm (EX-99.1) — 14KB
• 0001654954-25-012641.txt ( ) — 856KB
• ptn-20251105.xsd (EX-101.SCH) — 5KB
• ptn-20251105_lab.xml (EX-101.LAB) — 14KB
• ptn-20251105_cal.xml (EX-101.CAL) — 1KB
• ptn-20251105_pre.xml (EX-101.PRE) — 9KB
• ptn-20251105_def.xml (EX-101.DEF) — 2KB
• ptn_8k_htm.xml (XML) — 4KB

01 Entry into a Material Agreement

Item 1.01 Entry into a Material Agreement. On November 5, 2025, Palatin Technologies, Inc. entered into an underwriting agreement with A.G.P./Alliance Global Partners (the " Underwriting Agreement ") relating to the Company's public offering of 2,430,769 shares of common stock (or pre-funded warrants in lieu thereof) together with Series J warrants to purchase up to 2,430,769 shares of common stock (the " Series J Warrants "), and Series K warrants to purchase up to 2,430,769 shares of common stock (the " Series K Warrants ") at a combined public offering price of $6.50 per share of common stock and accompanying Series J and Series K Warrants (the " Offering "). Each Series J Warrant will have an exercise price of $6.50 per share and will be immediately exercisable. The Series J Warrants will expire on the earlier of (i) the eighteen-month anniversary of the original issuance date or (ii) on the 31st calendar day following the date that the Company receives the U.S. Food and Drug Administration (" FDA ") acceptance of the Company's Investigational New Drug for an in-house obesity treatment compound (long-acting peptide or oral small molecule) (the " FDA Exercise Period "). Each Series K Warrant will have an exercise price of $8.125 per share and will be immediately exercisable. The Series K Warrants will expire on the five-year anniversary of the original issuance date, however, if a holder's Series J Warrants have not been terminated in accordance with their terms prior to the expiration of the FDA Exercise Period, such holder's Series K Warrants will terminate automatically upon the earlier of the (i) eighteen-month anniversary of the original issuance date of the Series J Warrants or (ii) the expiration of the FDA Exercise Period and prior to the five-year anniversary of the issuance of the Series K Warrant. The gross proceeds to Palatin from the Offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be

01 Other Events

Item 8.01 Other Events. NYSE American Listing Compliance On August 11, 2025, a reverse stock split of the Company's outstanding shares of common stock took effect at a ratio of one-for-fifty (the " Reverse Stock Split "). The Reverse Stock Split resulted in the Company becoming compliant with Section 1003(f)(v) of the NYSE American Company Guide. On November 5, 2025, the Company submitted to NYSE American, on a pro-forma basis, as of November 5, 2025, financial statements demonstrating its compliance with the NYSE American continued listing standard under Section 1003(a)(iii) of the NYSE American Company Guide (the " Stockholders Equity Rule") , which requires the stockholder's equity to be greater than $6.0 million, after reflecting all quarter ended September 30, 2025 and October 1, 2025 to November 5, 2025, operations, revenue and expenses, and the equity offering (referenced above). This resulted in a significant increase to stockholders' equity since the Company's fiscal year end of June 30, 2025. The significant increase is primarily based on (i) closing of a business development collaboration with Boehringer Ingelheim International GmbH ("Boehringer Ingelheim") in August 2025, which resulted in revenue of $8.8 in the quarter ended September 30, 2025, and (ii) the planned of Offering of $15.8 million in gross proceeds, with $14.7 million of net proceeds expected to close November 12, 2025. 2 Accordingly, the closing of the Offering will result in the Company regaining compliance with NYSE American continued listing standard under Section 1003(a)(iii) of the NYSE American Company Guide (the " Stockholders' Equity Rule ") of greater than $6.0 million of stockholders' equity, and meeting all applicable requirements for continued listing on NYSE American, as of the date of this current report on Form 8-K (this " Current Report ").Effective November 12, 2025, Palatin's common stock is expected to resume trading on the NYSE American exchange under the symb

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements. These forward-looking statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "will" and "expected", or the negative of such terms, or other comparable terminology. Forward-looking statements, including statements regarding the Company's common stock being reinstated for trading on the NYSE American, are statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report on Form 8-K, and the Company expressly disclaims any obligation or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in the Company's expectations with regard thereto or any other change in events, conditions, circumstances, on which any such statement is based, except to the extent otherwise required by applicable law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated November 5, 2025, by and among Palatin Technologies, Inc. and A.G.P./Alliance Global Partners. 4.1 Form of Pre-Funded Warrant. 4.2 Form of Series J Warrant. 4.3 Form of Series K Warrant. 99.1 Press Release, dated November 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 6, 2025 PALATIN TECHNOLOGIES, INC. /s/ Stephen T. Wills Stephen T. Wills, CPA, MST Executive Vice President, Chief Financial Officer and Chief Operating Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR